GlassScriptPhysician profile
Michael C Yonz
NPI 1457610917
$3,413.47
in general payments reported to CMS, 2019-2025
20 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $560 · 2021: $347 · 2022: $914 · 2023: $332 · 2024: $313 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Travel and Lodging: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.62 |
| Travel and Lodging | $268.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $1,583.87 | 2019-2025 | Avenir, Tapestry, Rosa |
| Ferring Pharmaceuticals INC. | $653.90 | 2019-2025 | Euflexxa |
| Team 1, LLC | $538.11 | 2020-2025 | |
| Smith+Nephew, INC. | $119.65 | 2020-2023 | Acufex |
| Bioventus LLC | $67.67 | 2020-2023 | Durolane |
| Ucb, INC. | $43.43 | 2021-2022 | |
| Amgen INC. | $43.23 | 2021 | |
| Nalu Medical, INC. | $37.70 | 2023-2024 | Nalu Neurostimulation System |
| Sanofi-Aventis U.S. LLC | $37.14 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.75 | 2022-2023 | Seglentis |
| Depuy Synthes Sales INC. | $36.69 | 2025 | Na |
| Pacira Pharmaceuticals Incorporated | $35.13 | 2019-2022 | |
| Vericel Corporation | $32.27 | 2019-2021 | |
| Innovation Technologies INC | $30.36 | 2023 | Irrisept |
| Heron Therapeutics, INC. | $30.00 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $26.37 | 2021 | |
| Spr Therapeutics, INC | $17.75 | 2025 | Sprint Pns System |
| Convatec INC. | $16.98 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.02 | 2021 | |
| Pfizer INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yonz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.